[{"from": "human", "value": "Please give me some details about this molecule. [C][C@@H1][C][N][Branch1][=Branch2][C][C@@H1][Branch1][Ring2][N][Ring1][=Branch1][C][C][C][=C][C][=Branch2][Ring2][#Branch1][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][C][=N][C][=C][Branch2][Ring1][#Branch1][C][=Branch1][Ring2][=N][Ring1][=Branch1][C][=C][N][C][=C][Ring1][Branch1][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][Cl][C][C][C][Ring1][Ring1]"}, {"from": "gpt", "value": "The molecule is a selective, reversible type I inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) with potential antineoplastic activity. Upon administration of FLT3 inhibitor HM43239, it reversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias."}]